Organisation paid for research Program year 2025 Source: CMS Open Payments

Doylestown Hospital

Neither a doctor nor a teaching hospital

Research payments

$1,494,359

715 payments

Through program year 2025, Doylestown Hospital is reported as receiving $1,494,359 in research payments, across 715 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$82,359	11
2024	Research	$118,789	30
2023	Research	$284,476	61
2022	Research	$259,823	111
2021	Research	$322,424	184
2020	Research	$222,615	161
2019	Research	$203,874	157

Breakdown

Who paid Research payments · program years 2019–2025

Novo Nordisk AS $491,924 425 payments
Boston Scientific Corporation $348,508 52 payments
GlaxoSmithKline, LLC. $217,997 59 payments
Eli Lilly and Company $70,626 6 payments
Bayer HealthCare Pharmaceuticals Inc. $63,626 27 payments
Medical Device Business Services, Inc. $61,802 32 payments
CSL Behring $56,508 45 payments
Amgen Inc. $44,569 3 payments
Intercept Pharmaceuticals, Inc. $33,726 11 payments
Akebia Therapeutics Inc $28,411 25 payments

Studies the money was for Research payments · program years 2019–2025

Ex9536-4388 $491,924 425 payments
Advent $228,696 35 payments
A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $140,931 40 payments
A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the E $77,066 19 payments
Advantage Af $62,471 15 payments
Advent Lto $57,341 2 payments
A Randomized Double-Blind Placebo-Controlled Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $44,966 2 payments
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR) $40,673 18 payments
BAY94-8862 LCM HFmr/pEF (EF 40%) $38,154 16 payments
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $32,813 26 payments

What the money was spent on Research payments · program years 2019–2025

Overhead $21,750 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.